Table 1 .
Interim and final data on key outcome measures from the VALUE Trial evaluating Valsartan and Amlodipine. The randomization to the two regimens was 1:1
| Hypertensive patients at high cardiovascular risk | ||||
|---|---|---|---|---|
| May’98 to August’00 | n=15,290 | May’98 to December’03 | n=15,245 | |
| Valsartan/Amlodipine | Valsartan/Amlodipine | |||
| Outcome measure | Events | RR | Events | RR |
| All deaths | 178/141 | 1.25 | 841/818 | 1.02 |
| All myocardial infarctions | 102/76 | 1.33 | 369/313 | 1.17 |
| All strokes | 124/92 | 1.34 | 322/281 | 1.14 |
| Hospitalization for heart failure | 104/112 | 0.92 | 354/400 | 0.88 |
| New onset diabetes | No data | – | 690/845 | 0.81 |